Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

NCT04620187 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Salivary Gland Cancer
HER2 Gene Mutation

Interventions

DRUG: Ado-trastuzumab (T) emtansine (T-DM1)
RADIATION: Standard of Care Radiotherapy
DRUG: Standard of Care Chemotherapy

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]